VIR · Company research
Vir Biotechnology, Inc. Common Stock (VIR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| VIR Nov 2026 14.000 call (VIR261120C00014000) Stock Price, News, Quote & History - Yahoo! Finance Canada | VIR Nov 2026 14.000 call (VIR261120C00014000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 19, 2026 | neutral | 0 | 0.6 |
| Why (VIR) Price Action Is Critical for Tactical Trading - Stock Traders Daily | Why (VIR) Price Action Is Critical for Tactical Trading Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 18, 2026 | neutral | 0 | 0.6 |
| Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News? - Yahoo Finance | Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 17, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology Stock Price Forecast. Should You Buy VIR? - StockInvest.us | Vir Biotechnology Stock Price Forecast. Should You Buy VIR? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? | Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.8 | 1 |
| Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? | Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.8 | 1 |
| Vir Biotechnology signs Gilead cancer deal with US$90M upfront - Mugglehead Investment Magazine | Vir Biotechnology signs Gilead cancer deal with US$90M upfront Mugglehead Investment Magazine | View source ↗ | Mugglehead Investment Magazine | Oct 15, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - What's Next? - MarketBeat | Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - What's Next? MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments - Benzinga | Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments Benzinga | View source ↗ | Benzinga | Oct 14, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology (VIR) Shares Surge Nearly 10% Premarket on $1. - GuruFocus | Vir Biotechnology (VIR) Shares Surge Nearly 10% Premarket on $1. GuruFocus | View source ↗ | GuruFocus | Oct 14, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engagers - Pharmaceutical Executive | Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engagers Pharmaceutical Executive | View source ↗ | Pharmaceutical Executive | Oct 14, 2026 | neutral | 0 | 0.6 |
| Vir, Gilead ink licensing deal worth up to $1.9B (VIR:NASDAQ) - Seeking Alpha | Vir, Gilead ink licensing deal worth up to $1.9B (VIR:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 14, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology Sells 1.76 Million Shares to Gilead in $25M Stock Deal - Kalkine Media | Vir Biotechnology Sells 1.76 Million Shares to Gilead in $25M Stock Deal Kalkine Media | View source ↗ | Kalkine Media | Oct 14, 2026 | neutral | 0 | 0.6 |
| Gilead gets exclusive rights to develop three experimental cancer drugs - Stock Titan | Gilead gets exclusive rights to develop three experimental cancer drugs Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology (NasdaqGS:VIR) Stock Price - Simply Wall Street | Vir Biotechnology (NasdaqGS:VIR) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Oct 13, 2026 | neutral | 0 | 0.6 |
| Intuit Stock Rallies Pre-Market Today And There’s An Anthropic Connection - Stocktwits | Intuit Stock Rallies Pre-Market Today And There’s An Anthropic Connection Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits | Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo! Finance Canada | Vir Biotechnology, Inc. (VIR) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology stock hits 52-week high at 11.96 USD - Investing.com | Vir Biotechnology stock hits 52-week high at 11.96 USD Investing.com | View source ↗ | Investing.com | Oct 9, 2026 | neutral | 0 | 0.6 |
| Vir Biotechnology (NasdaqGS:VIR) Stock Forecast & Analyst Predictions - Simply Wall Street | Vir Biotechnology (NasdaqGS:VIR) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| Aziz Sawaf, CFO of Vir Biotechnology (VIR), reports zero directly held common shares. - Stock Titan | Aziz Sawaf, CFO of Vir Biotechnology (VIR), reports zero directly held common shares. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.